EULAV Asset Management
- SEC CIK
- 0001540826
- Latest filing
- Jul 29, 2026
ICPT holding history
Intercept Pharmaceuticals, Inc. in every 13F filed by EULAV Asset Management, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ICPT overviewAll 13F holders of ICPTFull Q2 2026 holdings
- Shares (Q2 2023)
- 0
- Sold out in Q2 2023
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 9
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2023 | 0 | $0 | 0.0% | −195,000−100.0% | Sold out | Holders |
| Q1 2023 | 195,000 | $2.62M | 0.1% | 00.0% | Unchanged | Holders |
| Q4 2022 | 195,000 | $2.41M | 0.1% | −200,000−50.6% | Reduced | Holders |
| Q3 2022 | 395,000 | $5.51M | 0.2% | 00.0% | Unchanged | Holders |
| Q2 2022 | 395,000 | $5.46M | 0.2% | −55,000−12.2% | Reduced | Holders |
| Q1 2022 | 450,000 | $7.32M | 0.2% | 00.0% | Unchanged | Holders |
| Q4 2021 | 450,000 | $7.33M | 0.2% | −210,000−31.8% | Reduced | Holders |
| Q3 2021 | 660,000 | $9.80M | 0.3% | +325,000+97.0% | Added | Holders |
| Q2 2021 | 335,000 | $6.69M | 0.2% | 00.0% | Unchanged | Holders |
| Q1 2021 | 335,000 | $7.73M | 0.2% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.